Atopic DermatitisPhase 2NCT05694884
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
A Phase 2 study testing ASLAN004 in people with Atopic Dermatitis, run by ASLAN Pharmaceuticals at 27 sites in 2 countries.
Trial summary
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atopic Dermatitis
- What is being tested?
- ASLAN004
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 75 participants
- Where
- 27 sitesin 2 countries
- Study dates
- 21 Dec 2022to 28 Feb 2025
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female participants ≥18 years
- Willing and able to comply with clinic visits and study-related procedures
- Chronic AD present for at least 1 year prior to screening
- Have vIGA score of ≥3 (5-scale of 0 to 4) at baseline
- Have ≥10% BSA of AD involvement at baseline
- Have EASI ≥18 at screening and baseline
Show all 11Show fewer
- History of inadequate response to, intolerance to or contraindication to a stable regimen of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) as treatment for AD
- All participants must have previously been treated with dupilumab meeting one of the following conditions:
- Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab for at least 16 weeks duration;
- Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment;
- Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab or for any other reasons may enter the study with no required prior length of dupilumab treatment;
Who cannot join
- Use of immunosuppressive/immunomodulating drugs and/or therapies, JAK inhibitors, or phototherapy (including tanning booth/parlor) within 4 weeks prior to the Baseline visit
- Have an uncontrolled chronic disease that may require multiple intermittent use of systemic corticosteroids at Screening, as defined by the Investigator
- Have uncontrolled asthma that might require bursts of oral or systemic corticosteroids, or require either of the following due to ≥1 exacerbations within 12 months before Baseline:
- Systemic (oral and/or parenteral) corticosteroid treatment;
- Hospitalization for >24 hours;
- Have had systemic treatment with small molecule investigational drugs within 8 weeks or 5 half-lives (if known), whichever is longer, prior to the Baseline visit
Show all 13Show fewer
- Have received treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI) such as tacrolimus and pimecrolimus, topical phosphodiesterase inhibitors such as crisaborole, topical JAK inhibitors (commercial or investigational use), within 1 week prior to randomization
- Have inadequate organ function or abnormal lab results considered clinically significant by the Investigator at the Screening visit
- History of human immunodeficiency virus (HIV) or positive HIV serology at Screening
- Infected with hepatitis B or hepatitis C viruses. For Hepatitis B, all subjects will undergo testing for Hepatitis B Surface Antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb) during Screening. Subjects who are HBsAg positive are not eligible for the study. Subjects who are HBsAg negative and HBcAb positive will be tested for Hepatitis B Surface Antibody (HBsAb) and if HBsAb is positive, may be enrolled in the study; if HBsAb is negative, the subject is not eligible for the study. For Hepatitis C, all subjects will undergo testing for Hepatitis C antibody (HCVAb) during Screening. Subjects who are HCVAb positive are not eligible for the study. Active COVID-19 infection at Baseline.
- Have known liver cirrhosis and/or chronic hepatitis of any etiology
- Known diagnosis of active tuberculosis or non-tuberculous mycobacterial infection or latent tuberculosis unless it is well documented by a specialist that the patient has been adequately treated
- Allergen immunotherapy should be discontinued 6 months before randomization
Trial locations and contacts
27 sites in 2 countries.
27 sites in 2 countries
United States24 sites, 24 recruiting
- Recruiting
ASLAN Investigative Site
Auburn Hills, Michigan, 48326
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Birmingham, Alabama, 35244
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Boca Raton, Florida, 33486
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Charleston, South Carolina, 29407
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Charlotte, North Carolina, 28277
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
East Amherst, New York, 14051
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Encino, California, 91436
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Fountain Valley, California, 92708
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Hollywood, Florida, 33021
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Hollywood, Florida, 33436
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Johnston, Rhode Island, 02919
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Las Vegas, Nevada, 89148
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Long Beach, California, 90806
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Los Angeles, California, 90025
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Louisville, Kentucky, 40217
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Miami Lakes, Florida, 33014
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
New Albany, Indiana, 47150
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
North Miami Beach, Florida, 33162
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Oklahoma City, Oklahoma, 73118
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Orange City, Florida, 32720
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Quincy, Massachusetts, 02169
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Saint Augustine, Florida, 32080
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Sherman Oaks, California, 91403
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
St. Petersburg, Florida, 33705
contact@aslanpharma.com
Canada3 sites, 3 recruiting
- Recruiting
ASLAN Investigative Site
Hamilton, Ontario, L8LCC3
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Ottawa, Ontario, K1H1E4
contact@aslanpharma.com
- Recruiting
ASLAN Investigative Site
Toronto, Ontario
M5A3R6, contact@aslanpharma.com
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
- Conditions
- Atopic Dermatitis
- Being tested
- Placebo, ASLAN004
- Keywords
- atopic dermatitis, IL-13, ASLAN004, IL-13Rα1, Eczema, Anti-IL-13Rα1, atopic eczema
- Medical subject headings
- Dermatitis, Atopic, Eczema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Placebo Comparator
ASLAN004Drug
ASLAN004
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every week (QW) from Week 2 to Week 15 Receives: Drug: Placebo |
| ASLAN004 | Experimental | Week 0, 1: LD of 600 mg; Week 2 through Week 15 QW: 400 mg dose Receives: Drug: ASLAN004 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent change from Baseline in Eczema Area and Severity Index (EASI) at Week 16
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD
Measured: Baseline, Week 16
Secondary outcomes (17)
Proportion of participants achieving validated Investigator's Global Assessment (vIGA) response of 0 (clear) or 1 (almost clear) at Week 16
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear)
Measured: Week 16
Proportion of participants with a 75% reduction Eczema Area and Severity Index 75 (EASI)
EASI scores range from 0 to 72 (severe)The EASI responder is defined as a participant who achieves a ≥75% improvement (EASI 75) from baseline in the EASI score
Measured: Week 16
Proportion of participants achieving EASI 50
EASI scores range from 0 to 72 (severe)The EASI responder is defined as a participant who achieves a ≥50% improvement (EASI 50) from baseline in the EASI score
Measured: Week 16
Proportion of participants achieving EASI 90
EASI scores range from 0 to 72 (severe)The EASI responder is defined as a participant who achieves a ≥90% improvement (EASI 90) from baseline in the EASI score
Measured: Week 16
Proportion of participants with EASI <7
EASI scores range from 0 to 72 (severe)
Measured: Week 16
Absolute and percent change in peak Pruritus Numerical Rating Scale (P-NRS)
The P-NRS is an 11-point scale used by patients to assess their worst itch severity over the past 24 hours, with 0 indicating no itch and 10 indicating the worst itch imaginable. Pruritus assessments will be recorded daily by the patient using an electronic diary
Measured: Week 16 and Week 24
Proportion of participants achieving a 4-point reduction in peak Pruritus Numerical Rating Scale
Pruritus Numerical Rating Scale
Measured: Week 16
Change in Body Surface Area (BSA) affected with AD
BSA ranges from 0% to 100 % with higher values representing greater extent of AD
Measured: Week 16 and Week 24
Change in SCORing Atopic Dermatitis (SCORAD)
The SCORAD is a validated measure of the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition
Measured: Week 16 and Week 24
Change in Dermatology Life Quality Index (DLQI)
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the patient's perception of the impact of AD disease symptoms and treatment on their quality of life (QoL). The 10 questions assess QoL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease). A high score is indicative of a poor QoL
Measured: Week 16 and Week 24
Change in Patient-Oriented Eczema Measure (POEM)
The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor QoL)
Measured: Week 16 and Week 24
Change in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm
The EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranges from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine
Measured: Week 16 and Week 24
Absolute and percent change in sleep disturbance numerical rating scale (SD-NRS)
The SD-NRS is an 11-point scale used by patients to assess their sleep disturbance severity over the past 24 hours, with 0 indicating no or minimal sleep disturbance and 10 indicating the worst imaginable sleep disturbance. SD-NRS assessments will be recorded daily by the patient using an electronic diary
Measured: Week 16 and Week 24
Proportion of participants achieving a 4-point reduction in sleep disturbance numerical rating scale
Measured: Week 16
Percent change from baseline of validated Investigator's Global Assessment (vIGA)
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear)
Measured: Week 24
Percent change from baseline of Eczema Area and Severity Index
EASI scores range from 0 to 72 (severe)
Measured: Week 24
Number of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) from study drug administration
Measured: Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2023
- Study start21 Dec 2022
- Primary completion31 Dec 2024 (estimated)
- Study completion28 Feb 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic DermatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- ASLAN Pharmaceuticals
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chief Medical Officer, Study director, ASLAN Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05694884
- Sponsor's protocol ID
- ASLAN004-004
- Status last verified
- Jan 2024
- First submitted
- 9 Jan 2023
- Last updated
- 18 Jan 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
- ClinicalTrials.gov ID
- NCT05694884
- Acronym / sponsor ID
- ASLAN004-004
- Conditions
- Atopic Dermatitis
- Keywords
- atopic dermatitis, IL-13, ASLAN004, IL-13Rα1, Eczema, Anti-IL-13Rα1, atopic eczema
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- ASLAN PharmaceuticalsUniversity, hospital or other
- Study start
- 21 Dec 2022 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 28 Feb 2025 (estimated)
- First posted
- 23 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboPlacebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every week (QW) from Week 2 to Week 15 |
| ASLAN004 | Experimental | Drug: ASLAN004Week 0, 1: LD of 600 mg; Week 2 through Week 15 QW: 400 mg dose |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Male or female participants ≥18 years
- Willing and able to comply with clinic visits and study-related procedures
- Chronic AD present for at least 1 year prior to screening
- Have vIGA score of ≥3 (5-scale of 0 to 4) at baseline
- Have ≥10% BSA of AD involvement at baseline
Key exclusion criteria (13 listed)
- Use of immunosuppressive/immunomodulating drugs and/or therapies, JAK inhibitors, or phototherapy (including tanning booth/parlor) within 4 weeks prior to the Baseline visit
- Have an uncontrolled chronic disease that may require multiple intermittent use of systemic corticosteroids at Screening, as defined by the Investigator
- Have uncontrolled asthma that might require bursts of oral or systemic corticosteroids, or require either of the following due to ≥1 exacerbations within 12 months before Baseline:
- Have had systemic treatment with small molecule investigational drugs within 8 weeks or 5 half-lives (if known), whichever is longer, prior to the Baseline visit
- Have received treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI) such as tacrolimus and pimecrolimus, topical phosphodiesterase inhibitors such as crisaborole, topical JAK inhibitors (commercial or investigational use), within 1 week prior to randomization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboPlacebo Comparator | Drug | Placebo |
| ASLAN004ASLAN004 | Drug | ASLAN004 |
Primary outcome
Percent change from Baseline in Eczema Area and Severity Index (EASI) at Week 16
Time frame: Baseline, Week 16
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD
17 secondary outcomes
Proportion of participants achieving validated Investigator's Global Assessment (vIGA) response of 0 (clear) or 1 (almost clear) at Week 16
Time frame: Week 16
Proportion of participants with a 75% reduction Eczema Area and Severity Index 75 (EASI)
Time frame: Week 16
Proportion of participants achieving EASI 50
Time frame: Week 16
Proportion of participants achieving EASI 90
Time frame: Week 16
Proportion of participants with EASI <7
Time frame: Week 16
Absolute and percent change in peak Pruritus Numerical Rating Scale (P-NRS)
Time frame: Week 16 and Week 24
Proportion of participants achieving a 4-point reduction in peak Pruritus Numerical Rating Scale
Time frame: Week 16
Change in Body Surface Area (BSA) affected with AD
Time frame: Week 16 and Week 24
Change in SCORing Atopic Dermatitis (SCORAD)
Time frame: Week 16 and Week 24
Change in Dermatology Life Quality Index (DLQI)
Time frame: Week 16 and Week 24
Change in Patient-Oriented Eczema Measure (POEM)
Time frame: Week 16 and Week 24
Change in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm
Time frame: Week 16 and Week 24
Absolute and percent change in sleep disturbance numerical rating scale (SD-NRS)
Time frame: Week 16 and Week 24
Proportion of participants achieving a 4-point reduction in sleep disturbance numerical rating scale
Time frame: Week 16
Percent change from baseline of validated Investigator's Global Assessment (vIGA)
Time frame: Week 24
Percent change from baseline of Eczema Area and Severity Index
Time frame: Week 24
Number of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) from study drug administration
Time frame: Week 24
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for Atopic Dermatitis
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chief Medical Officer study director
ASLAN Pharmaceuticals
27 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing ASLAN004 in people with Atopic Dermatitis, run by ASLAN Pharmaceuticals at 27 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 27 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact ASLAN Pharmaceuticals (+65 6817 9598, contact@aslanpharma.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent change from Baseline in Eczema Area and Severity Index (EASI) at Week 16 (time frame: Baseline, Week 16). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2024.